Wednesday June 18, 2025 8:30am - 9:30am EDT
Speakers AB
Chief Executive Officer, Soleno Therapeutics Inc, United States
Dr. Bhatnagar, CEO of Soleno since its inception in 2017, brings over 20 years of medical expertise to the biopharmaceutical and medical device industries. His extensive background encompasses the development of biologics, drugs, drug-device combinations, and diagnostic/therapeutic...
Read More → 
Deputy Director, Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, United States
Philip J. (P.J.) Brooks is the deputy director of NCATS’ Division of Rare Diseases Research Innovation. Brooks represents NCATS in the NIH-wide Gene Therapy Working Group, the Regenerative Medicine Innovation Project and the International Rare Diseases Research Consortium (IRDiRC...
Read More →
Chief of Policy, Advocacy, and Patient Engagement, EveryLife Foundation for Rare Diseases, United States
Annie has served within the community for nearly three decades through her roles with Parent Project Muscular Dystrophy (PPMD) and the Muscular Dystrophy Association (MDA). In that time she helped lead legislative efforts around passage and implementation of the MD-CARE Act (2001...
Read More →MK
CEO, PTC Theraputics, United States
Dr. Matthew Klein is CEO or PTC Therapeutics, a global biopharmaceutical company that discovers, develops and commercializes innovative therapies for rare disorders. Dr. Klein completed his undergraduate degree at the University of Pennsylvania graduating summa cum laude and Phi Beta...
Read More → 
Assoc. Dir. for Rare Diseases; Program Manager, Accelerating Rare Disease Cures, FDA, United States
Dr. Kerry Jo Lee is a pediatric gastroenterologist/hepatologist and the Associate Director for Rare Diseases in the Office of New Drugs (OND), CDER. In this role she leads CDER’s Rare Diseases Team and the Accelerating Rare disease Cures (ARC) Program. Dr. Lee joined the FDA in...
Read More →
Vice President, Head of Regulatory Science and Execution, Alexion, United States
Kim Quaintance-Lunn is Vice President, Head of Regulatory Science & Execution, for Alexion Pharmaceuticals; Strategic Advisor to the DIA Board of Directors; and Director at Large and Treasurer for the FDA Alumni Association. At Alexion, Kim is responsible for leading and implementing...
Read More →
Director, Hyman, Phelps & McNamara, PC, United States
James Valentine, JD, MHS is an attorney at Hyman, Phelps & McNamara where he assists medical product industry and patient advocacy organization clients in a wide range of regulatory matters, including new drug and biologic development and approval issues. Mr. Valentine has been central...
Read More →
Wednesday June 18, 2025 8:30am - 9:30am
EDT
146BC
Walter E. Washington Convention Center 801 Allen Y. Lew Place, NW Washington, DC 20001-3614 USA
